BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's Dementia -April 10, 2024 at 07:01 am EDT

Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN, Conn., April 10, 2024 -- BioXcel...

Related Keywords

Erik Kopp ,Vincent Oneill ,David Schull ,Brennan Doyle ,Scott Stachowiak ,Nasdaq ,Product Development ,Bioxcel Therapeutics Inc ,Securities Exchange ,Globenewswire Inc ,While The Company ,Bioxceltherapeutics Inc ,Drug Administration ,Xcel Therapeutics ,Care Phase ,Breakthrough Therapy ,Vincento Neill ,Medical Officer ,Care Pivotal Phase ,Negative Syndrome Scale Excitatory Component ,Prescribing Information ,Fast Track ,Mental State Examination ,Onkosxcel Therapeutics ,Private Securities Litigation Reform Act ,Securities Act ,Securities Exchange Act ,Annual Report ,Bioxcel Therapeutics ,Markets ,